BGDO Educational webinar

🔹17 June - 19:30 | PDAC and Esophagogastric Cancers > go to details

🔹 20 November - 19:30  | Lower GI Cancers

BGDO Educational Webinar: NET & HCC/Cholangioca: new developments and case discussions- 18 March > Replay

BGDO Annual Meeting -  Saturday 10 January 2026 

Launch of the international SAFIR ABC10 program. The first precision medicine initiative for advanced biliary tract cancers, is now open for recruitment in the UK and France. Recruitment will also soon open in Belgium.> read press release

BGDO Educational Webinar: Post ESMO updates - 5 November 2024 > Go to details

BGDO FFCD cours intensif en cancérologie: 10 - 11 Oct. 2024 > Go to details

Reimbursement criteria for MOC/COM:

• The DGEC / SECM (dienst voor geneeskundige evaluatie en controle / Service d'évaluation et de contrôle médicaux) has been working on the reimbursement criteria for MOC/COM.
  As a result, payments for several MOC/COM reports have been refused, especially in neuro-oncology but also for diverse reasons over all kinds of tumours. There has been a meeting with several actors on the field and DGEC has promised to send out a communication to the hospitals about the rules they apply for the moment. While we understand that rules are necessary and the budget has to be kept reasonable, we also believe that correct payment for valuable work is necessary. Therefore, a working group has been set up in order to work urgently on a new proposal for fair reimbursement of MOC/COM meetings.

BGDO Educational webinar: Post ENETS and ASCO GI ! - 25 April 2024 > Go to details

BGDO Annual Meeting: Brainpuzzles in GI cancer - 13 January 2024 > Go to details

BGDO Educational  webinar: ASCO and ESMO Updates -   7  November 2023 >replay is available

BGDO Educational program: What you really need to know on NEN and pancreaticobiliary tumors! - 25 April 2023 > Go to details

BGDO Annual Meeting: Genetics, Genomics and Clinics  -  14 January 2023 - replay is available

BGDO New Board 2022 -2025  Alain Hendlisz - president, Karen Geboes - vice president, Leen Mortier - Secretary , Eric Van Cutsem - Treasurer, Ivan Borbath, Javier Carrasco, Saskia Carton, Veerle Casneuf, Anne Demols, Marc Peeters, Sabine Tejpar, Marc Van den Eynde, Jean-Luc Van Laethem

The joint advice on screening for DPD-deficiency in patients treated with 5-FU, initiated by the Belgian Group of Digestive Oncology (BGDO) and endorsed by the Belgian Society of Medical Oncology (BSMO), College of Genetics (CG), Toxicological Society of Belgium and Luxembourg (BLT) has been published in ACTA CLINICA BELGICA. We all invite you to read the article. Go to the abstract 

BGDO Award 2023 - Congratulations to Filip Van Herpe, UZ Leuven for his project on "A multicenter prospective analysis evaluating ctDNA in up front resectable esophageal cancer. Can ctDNA potentially influence treatment options?"

BGDO DNET Award 2023 - Congratulations to Julien Pierrard Cliniques Saint-Luc, Brussels for his project on "Immune-priming effect of Radiotherapy in metastatic colorectal cancer."

REACHIN trial: Results published in the Annals of Oncology on 24 May 2020
Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: a randomized, double-blind, phase 2 trial – REACHIN

BGDO TRIALS presented at ESMO and ASCO-GI Results of the MAGNET, QOLINPAC and REACH-IN trials are communicated in international congresses
MAGNET and QOLINPAC are accepted as poster and poster discussion at the forthcoming ESMO, and REACH-IN is sent as abstract for presentation at ASCO-GI.

The BGDO has been recognized legally as Sponsor for non-commercial clinical trials,which is a huge step forward for the implementation of new trials, and the development of the BGDO as a valid and reliable partner with other collaborative groups.